Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31572500 | 0.84 | AOC3 (0.59) | PPARGCHRM2CHRM1CHRM3L3MBTL1 | |
| SCHEMBL936657 | 0.83 | MAOA (0.43) | PPARGL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL937208 | 0.83 | ADRB3 (0.48) | — | |
| SCHEMBL2886168 | 0.82 | PPARG (0.56) | PPARGCHRM2CHRM1CHRM3L3MBTL1 | |
| SCHEMBL937188 | 0.82 | KMT2A (0.49) | ALDH1A1MAPK1NPC1RAB9AKDM4E | |
| SCHEMBL936475 | 0.82 | KMT2A (0.49) | ALDH1A1MAPK1NPC1RAB9AKDM4E | |
| SCHEMBL936476 | 0.82 | KMT2A (0.49) | ALDH1A1MAPK1NPC1RAB9AKDM4E | |
| SCHEMBL14479923 | 0.80 | L3MBTL1 (0.48) | PPARGCHRM2CHRM1CHRM3L3MBTL1 | |
| SCHEMBL937364 | 0.80 | PIM1 (0.63) | PPARGNPC1RAB9A | |
| SCHEMBL14479922 | 0.80 | L3MBTL1 (0.48) | PPARGCHRM2CHRM1CHRM3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202401-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CIRIUS THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2513070-B1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3202401-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Octeta Therapeutics, LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2512470-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OCTETA THERAPEUTICS LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| EP-2931274-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Metabolic Solutions Development Company LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9126959-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8912335-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2014093114-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2011133611-A1 | THIAZOLIDINEDIONE ANALOGUES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011084453-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084459-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084456-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011075514-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010105048-A9 | THIAZOLIDINEDIONE ANALOGUES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010105048-A1 | THIAZOLIDINEDIONE ANALOGUES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | CIRIUS THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| EP-2203433-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | Metabolic Solutions Development Company (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009038681-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | AGTR2, ADRB1, ADRB3 | PPARG 42/4885CHRM2 1404/4885CHRM1 1851/4885 |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885CHRM2 1891/4885CHRM1 2394/4885 |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885CHRM2 1191/4885CHRM1 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.